Gabriela Hobbs, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Abbvie
    Topic:
    myelofibrosis
    Date added:
    01/23/2023
    Date updated:
    01/23/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Novartis
    Topic:
    CML
    Date added:
    01/23/2023
    Date updated:
    01/23/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Pfizer
    Topic:
    CML
    Date added:
    01/23/2023
    Date updated:
    01/23/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    BMS
    Topic:
    myelofibrosis
    Date added:
    01/23/2023
    Date updated:
    01/23/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Pharmaxis
    Topic:
    myelofibrosis
    Date added:
    01/23/2023
    Date updated:
    01/23/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Cogent
    Topic:
    Mastocytosis
    Date added:
    01/23/2023
    Date updated:
    01/23/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Morphosys
    Topic:
    myelofibrosis
    Date added:
    01/23/2023
    Date updated:
    01/23/2023
  • Attribution:
    Self
    Type of financial relationship:
    Financial Support
    Ineligible company:
    Incyte
    Topic:
    Myelofibrosis
    Date added:
    01/23/2023
    Date updated:
    01/23/2023
Return to 2023 Annual Summit on Hematologic Cancers: Incorporation of Novel Therapies in Clinical Practice